A recently initiated phase I trial, the AUGMENT-102 (NCT05326516), will provide confidence in pediatric dosing of revumenib in combination with chemotherapy as it includes both children and adults with R/R KMT2A-r, NUP98-r and NPM1c acute leukemias and aims to determine the safety and tolerability of revumenib in combination with standard myeloid and lymphoid chemotherapy backbones (Table 2). The gene discussed is NUP98; the disease is acute leukemia.